← Leaderboards
Markus H. Frank
Brigham And Women'S Hospital
$10,452,698
Attributed
$20,282,699
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.5M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$29,285,123 · 10
By mechanism
R01$11,962,377 · 5
P01$11,024,941 · 3
R24$5,912,245 · 1
K08$385,560 · 1
Top collaborators
- Natasha Y Frank19 shared
- Bruce R Ksander15 shared
- George F Murphy13 shared
- Frank S Hodi5 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- George F Murphy$7,377,470
- Natasha Y Frank$4,964,719
- Gregory L Stahl$14,189,628
- Christine Guo Lian$2,178,309
- Richard Carl Krolewski$738,683
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsStem CellsSkinLaboratoriesIn VitroSelf-RenewalPathway InteractionsGenesChronicStem Cell TransplantAllogenicNatural RegenerationSuccessNovel StrategiesMalignant NeoplasmsIn VivoTissuesSourceRepairedStem Cell PopulationAutologousMonoclonal AntibodiesRegenerativeMulti-Drug Resistance
Grant awards (45)
Multicomponent Therapy for Age-related Skin Stem Cell Deficiency$2,187,178
P01 · FY2025 · AG
ABCB5-positive stem cells for LSCD therapy$761,966
R01 · FY2025 · EY · contact PI
Skin-Intrinsic Immunosuppressive Mesenchymal Stem Cells and aGVHD$413,768
R01 · FY2025 · HL
Stem Cell Integral Membrane Transporter ABCB5 and Dermal Regeneration$364,529
P01 · FY2025 · AG · contact PI
Multicomponent Therapy for Age-related Skin Stem Cell Deficiency$2,231,814
P01 · FY2024 · AG
ABCB5-positive stem cells for LSCD therapy$761,966
R01 · FY2024 · EY · contact PI
Stem Cell Integral Membrane Transporter ABCB5 and Dermal Regeneration$538,988
P01 · FY2024 · AG · contact PI
Skin-Intrinsic Immunosuppressive Mesenchymal Stem Cells and aGVHD$405,493
R01 · FY2024 · HL
Multicomponent Therapy for Age-related Skin Stem Cell Deficiency$2,231,812
P01 · FY2023 · AG
ABCB5-positive stem cells for LSCD therapy$801,142
R01 · FY2023 · EY · contact PI
Stem Cell Integral Membrane Transporter ABCB5 and Dermal Regeneration$538,988
P01 · FY2023 · AG · contact PI
Skin-Intrinsic Immunosuppressive Mesenchymal Stem Cells and aGVHD$413,768
R01 · FY2023 · HL
Multicomponent Therapy for Age-related Skin Stem Cell Deficiency$2,351,620
P01 · FY2022 · AG
Multipotent ABCB5-positive cell therapeutics for corneal disease$1,176,331
R24 · FY2022 · EY
Stem Cell Integral Membrane Transporter ABCB5 and Dermal Regeneration$580,012
P01 · FY2022 · AG · contact PI
Skin-Intrinsic Immunosuppressive Mesenchymal Stem Cells and aGVHD$433,517
R01 · FY2022 · HL
Multipotent ABCB5-positive cell therapeutics for corneal disease$1,176,331
R24 · FY2021 · EY
Multipotent ABCB5-positive cell therapeutics for corneal disease$1,176,331
R24 · FY2020 · EY
ABCB5-positive stem cells for LSCD therapy$487,236
R01 · FY2020 · EY · contact PI
Multipotent ABCB5-positive cell therapeutics for corneal disease$1,176,331
R24 · FY2019 · EY
ABCB5-positive stem cells for LSCD therapy$489,489
R01 · FY2019 · EY · contact PI
Multipotent ABCB5-positive cell therapeutics for corneal disease$1,206,921
R24 · FY2018 · EY
ABCB5-positive stem cells for LSCD therapy$491,647
R01 · FY2018 · EY · contact PI
ABCB5-positive stem cells for LSCD therapy$598,457
R01 · FY2017 · EY · contact PI
ABCB5-positive stem cells for LSCD therapy$275,698
R01 · FY2017 · EY · contact PI
ABCB5-positive stem cells for LSCD therapy$534,234
R01 · FY2016 · EY · contact PI
Immunology of human malignant melanoma initiating cells$364,127
R01 · FY2016 · CA · contact PI
ABCB5-positive stem cells for LSCD therapy$104,732
R01 · FY2016 · EY · contact PI
Immunology of human malignant melanoma initiating cells$364,127
R01 · FY2015 · CA · contact PI
Immunology of human malignant melanoma initiating cells$353,203
R01 · FY2014 · CA · contact PI
Immunology of human malignant melanoma initiating cells$377,059
R01 · FY2013 · CA · contact PI
Immunology of human malignant melanoma initiating cells$401,127
R01 · FY2012 · CA · contact PI
Melanoma Stem Cells, Vasculogenesis and Neoplastic Progression$336,640
R01 · FY2012 · CA · contact PI
Melanoma Stem Cells, Vasculogenesis and Neoplastic Progression$337,560
R01 · FY2011 · CA · contact PI
Melanoma Stem Cells, Vasculogenesis and Neoplastic Progression$343,699
R01 · FY2010 · CA · contact PI
ABCB5 P-Glycoprotein in Cancer Multidrug Resistance$291,276
R01 · FY2010 · CA · contact PI
Melanoma Stem Cells, Vasculogenesis and Neoplastic Progression$327,598
R01 · FY2009 · CA · contact PI
ABCB5 P-Glycoprotein in Cancer Multidrug Resistance$291,276
R01 · FY2009 · CA · contact PI
Melanoma Stem Cells, Vasculogenesis and Neoplastic Progression$319,045
R01 · FY2008 · CA · contact PI
ABCB5 P-Glycoprotein in Cancer Multidrug Resistance$291,276
R01 · FY2008 · CA · contact PI
ABCB5 P-Glycoprotein in Cancer Multidrug Resistance$291,276
R01 · FY2007 · CA · contact PI
ABCB5 P-Glycoprotein in Cancer Multidrug Resistance$299,975
R01 · FY2006 · CA · contact PI
P-glycoprotein Function in Allograft Rejection$128,520
K08 · FY2004 · AI
P-glycoprotein Function in Allograft Rejection$128,520
K08 · FY2003 · AI
P-glycoprotein Function in Allograft Rejection$128,520
K08 · FY2002 · AI